Get Our Latest Stock Report on IVVD Invivyd Price Performance Shares of IVVD stock opened at $2.04 on Thursday. Invivyd has a 1-year low of $0.35 and a 1-year high of $5.10. The stock’s 50-day ...

Invivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has seen sales of its COVID-19 product fall well short of expectations, is ...

Invivyd's Q4 2024 Pemgarda revenue hit $13.8 million, up 48% from Q3, with $69.3 million in year-end cash reserves. Get real-time earnings alerts before the market moves and access expert analysis ...

In this article, we are going to take a look at where Invivyd Inc (NASDAQ:IVVD) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two ...

Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% ...

Invivyd, Inc. (NASDAQ:IVVD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Invivyd, Inc., a commercial-stage biopharmaceutical ...

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 ...

Invivyd has a 52-week low of $0.38 and a 52-week high of $5.20. The stock’s 50-day simple moving average is $0.53 and its 200 day simple moving average is $0.85. Insiders Place Their Bets ...

Invivyd is poised to support PEMGARDA commercial efforts and anticipates continued revenue growth along with operational efficiency improvements. Preliminary financial results are unaudited and ...

Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and potential long-term risks of COVID-19 to the broad ...

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced ...